ArticleEJNMMI research2022
Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study.
Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- A histo-clinical score to predict evolution to radioactive iodine-refractory of the follicular cell-derived thyroid carcinoma (PREDIRAIR): a single-centre, prospective, cohort study.EClinicalMedicine · 2026Article
- Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Frontiers in endocrinology · 2026Article
- Gene Expression Analysis of Papillary Thyroid Carcinoma With Lymph Node Metastasis and Radioiodine Refractivity.Cureus · 2025Article
- Article
- The ability of anexelekto (AXL) expression and TERT promoter mutation to predict radioiodine-refractory differentiated thyroid carcinoma.Diagnostic pathology · 2025Article
- Early detection of mild cognitive impairment utilizing ocular biomarker-based risk scoring nomogram.Frontiers in aging neuroscience · 2025Article
- The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC).Journal of clinical & translational endocrinology · 2024Article
- Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma.World journal of nuclear medicine · 2024Article
- Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.Journal of endocrinological investigation · 2024Article
- Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review.Frontiers in endocrinology · 2024Review
- Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.Frontiers in endocrinology · 2024Article
- A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiated thyroid carcinoma (DTC) originates from abnormal follicular cells and accounts for approximately 90-95% of thyroid malignancies. The diagnosis of radioiodine refractory DTC (RR-DTC) is based on clinical evolution and iodine uptake characteristics rather than pathological characteristics. Thus, it takes a long time to become apparent, and the definition of RR-DTC covers multiple aspects. We aimed to analyze the clinical and molecular imaging characteristics of patients with RR-DTC and identify independent predictors to develop an RR-DTC scoring system and a simple nomogram for predicting the probability of RR-DTC. We reviewed the data of 404 patients with metastatic DTC who underwent both post-RAI WB therapy scintigraphy and
resultsDiagnosis at age ≥ 48 years (OR, 1.037; 95% confidence interval [CI], 1.007-1.069), recurrence between the operation and iodine-131 treatment (OR, 7.362; 95% CI 2.388-22.698), uptake of
conclusionsWe demonstrated that a predictive model based on four factors has a good ability to predict RR-DTC. An index score ≥ 10 points was found to be the optimal index point for predicting RR-DTC. Moreover, this nomogram model has good predictive ability and stability. This model may help establish an active surveillance or appropriate treatment strategy for RR-DTC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.